Verrica Pharmaceuticals Inc

NASDAQ:VRCA   10:16:23 AM EDT
9.72
+0.46 (+4.97%)
Products

Verrica Pharmaceuticals Announces FDA Acceptance Of Its Ind Application For LTX-315

Published: 11/18/2021 12:55 GMT
Verrica Pharmaceuticals Inc (VRCA) - Verrica Pharmaceuticals Announces FDA Acceptance of Its Ind Application for Ltx-315, a Potential First-in-class Oncolytic Peptide-based Immunotherapy, for the Treatment of Basal Cell Carcinoma.
Verrica Pharmaceuticals Inc - Expects to Initiate Its Phase 2 Trial of Ltx-315 in Basal Cell Carcinoma in Q1 of 2022.